KYMR Earnings Date: Feb 25, 2027 (Estimated) — Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is KYMR's next earnings date?
Kymera Therapeutics, Inc. (KYMR) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.26 on revenue of $4.3M.
How did KYMR do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Kymera Therapeutics, Inc. posted EPS of -$1.32 versus the -$1.26 estimate, a miss of 4.8%. Revenue was $1.4M against a $3.3M estimate. The stock's 1-day post-earnings move was +0.1%.
How much does KYMR stock move after earnings?
KYMR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
🤖 AI Earnings Analysis
Positive KT-579 Phase 1 data—deep, sustained IRF5 degradation, biomarker modulation and favorable safety—strengthen Kymera’s clinical case, but Q3’s $1.32 loss per share missed estimates by $0.06; results remain mixed.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -1.26 | -1.32 | -4.76% | $1.4M | ❌ Miss | +0.07% | — | — |
| 2026-08-05 | Q2 2026 | -0.71 | -0.62 | +13.89% | $65.0M | ✅ Beat | +1.04% | +5.01% | +13.64% |
| 2026-04-30 | Q1 2026 | -0.86 | -0.71 | +17.44% | $34.4M | ✅ Beat | -0.54% | +5.83% | -0.11% |
| 2026-02-26 | Q4 2025 | -0.78 | -0.97 | -24.36% | $2.9M | ❌ Miss | +4.80% | -5.04% | -11.58% |
| 2025-11-04 | Q3 2025 | -0.76 | -0.90 | -18.42% | $2.8M | ❌ Miss | +0.32% | +2.58% | +10.50% |
| 2025-08-11 | Q2 2025 | -0.77 | -0.95 | -23.38% | $11.5M | ❌ Miss | -7.24% | +4.95% | +7.04% |
| 2025-02-27 | Q4 2024 | -0.79 | -0.88 | -11.39% | $7.4M | ❌ Miss | -14.45% | -10.35% | -14.59% |
| 2024-10-31 | Q3 2024 | -0.84 | -0.82 | +2.38% | $3.7M | ✅ Beat | -3.15% | +3.80% | -1.72% |
Showing last 8 quarters.